Based on these results, we propose that this new dosing strategy may be appropriate for those MF patients commencing ruxolitinib therapy due to splenomegaly and/or MF-associated symptoms who have clinically relevant anemia (Hb < 10 g/dl). This evidence concerns the gene GSTM1 and anemia (phenotype).